COMP <GO>
IONS vs JNJ // FREE CASH FLOW YIELD
Ionis Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IONS 4
— JNJ 8
▲ FREE CASH FLOW YIELD LEADER: JNJ
LAST: $43.52 (-1.96%) • MKT CAP: $7.38B
fcf-yield
-4.34%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IONS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IONS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 67.90% | +28.10 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.90% | 25.50% | -46.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -4.34% | 2.97% | -7.31 | JNJ | /fcf-yield <GO> |
| Operating Margin | -40.40% | 34.70% | -75.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -40.40% | 28.50% | -68.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 33.80% | 6.00% | +27.80 | IONS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.08 | 5.59 | -4.51 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 60.4 | -17.21 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.08 | +0.01 | IONS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 23.0x | -1.00 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.38B | $662.49B | -$655.11B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IONS REV | JNJ REV | IONS GROSS % | JNJ GROSS % | IONS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $943.7M | $94.19B | 98.3% | 67.9% | -$320.0M | $19.70B |
| FY 2024 | $705.1M | $88.82B | 98.4% | 69.1% | -$546.2M | $19.84B |
| FY 2023 | $787.6M | $85.16B | 44.0% | 44.0% | -$343.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IONS // BETA 1.09
JNJ // BETA 1.08